We further compared the patient stratification capabilities of c-MYC/MYCN targets with prognostic power, with the marker genes of different cell clusters during murine and human sympathoadrenal development [64,65] as well as in NB [66,67,68]. This evidence concerns the gene MYC and neuroblastoma.